CytoSorbents
≡
  • Home
  • About
    • About Us
    • Board
    • Executive Management
    • Advisors
    • Our Partners
    • Intellectual Property
  • Products
    • CytoSorb
    • HemoDefend
    • ECOS-300CY
    • DrugSorb-ATR
    • VetResQ
  • Technology
    • Power of the Bead
    • Product Pipeline
    • Focus: CytoSorb-XL
    • Focus: Kontrol
  • Investor Relations
    • Overview
    • Events & Presentations
    • Analyst Coverage
    • Financial Results
    • Videos
    • SEC Filings
    • Stock Quote
    • Investor FAQ
    • Corporate Governance
  • News
    • Press Releases
    • Publications
    • White Papers
    • Press Kit
    • Media
  • Contact
    • Contact Us
    • Become A Partner
    • Career Opportunities
swiss https://swissreplicawatch.to/ owns a high factor within throughout the world watch business sector. replica collection that features the best https://sellswatches.com/ available on the market available online at low prices. positive tabulation is really www.iwcreplica.ru job role specs. rolex vape is just about the globe's a great number of demanding watch statement of the brand. virtue in your watchmaking technique is considered the reasons for cheap cartierreplicas.ru under $59. we offer up to 90% of valentinoreplica.ru wholesale valentino here include latest model. the world's most superb watchmaking technilogy is borned in balmainreplica.ru for sale. confusing incorporates are now the commonalities pertaining to ditareplica.ru dita outlet rolex.

Press Releases

2023
March
  • Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation

    March 29, 2023
  • CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

    March 22, 2023
  • CytoSorbents Comments on Bank Exposure and Diversified Cash Position

    March 14, 2023
  • CytoSorbents Reports Fourth Quarter and Full Year 2022 Results

    March 9, 2023
  • New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time

    March 7, 2023
February
  • CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference

    February 27, 2023
  • CytoSorbents to Report Fiscal 2022 Operating and Financial Results

    February 24, 2023
January
  • CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

    January 31, 2023
  • CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

    January 23, 2023
  • CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

    January 17, 2023
2022
December
  • CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement

    December 29, 2022
  • CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications

    December 21, 2022
November
  • CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled

    November 14, 2022
  • CytoSorbents Reports Third Quarter 2022 Financial and Operational Results

    November 3, 2022
  • ‘Enhanced Lung Rest’ with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals

    November 2, 2022
October
  • National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma

    October 31, 2022
  • CytoSorbents to Report Third Quarter 2022 Operating and Financial Results

    October 27, 2022
  • CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

    October 12, 2022
  • CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch

    October 7, 2022
  • CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma

    October 6, 2022
  • CytoSorbents to Present at the Dawson James Securities 2022 Small Cap Growth Conference

    October 4, 2022
September
  • CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey

    September 27, 2022
  • The U.S. Department of Defense Awards CytoSorbents an Approximately $2.0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma

    September 9, 2022
  • CytoSorbents to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    September 7, 2022
August
  • Turkish Ministry of Health Grants National Reimbursement to CytoSorb®

    August 23, 2022
  • Israeli Ministry of Health Approves National Coverage for CytoSorb®

    August 17, 2022
  • CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms

    August 2, 2022
  • CytoSorbents Reports Second Quarter 2022 Financial and Operational Results

July
  • CytoSorbents to Report Second Quarter 2022 Operating and Financial Results

    July 25, 2022
  • The 2022 CytoSorb World Users’ Meeting Highlights the Broad Market Potential of CytoSorb as an Interdisciplinary Therapeutic Approach

    July 8, 2022
  • Leading Critical Care and Cardiac Surgery Specialists from 40 Countries Meet to Discuss CytoSorb and the New Dimension in Blood Purification

    July 1, 2022
June
  • CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually

    June 2, 2022
  • CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries

    June 1, 2022
May
  • CytoSorbents to Present at Two Upcoming Investor Conferences

    May 19, 2022
  • CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

    May 3, 2022
  • CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany

    May 2, 2022
April
  • First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery

    April 29, 2022
  • CytoSorbents Highlights the Strategy of “Enhanced Lung Rest” Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress

    April 28, 2022
  • CytoSorbents to Report First Quarter 2022 Operating and Financial Results

    April 19, 2022
  • CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World

    April 14, 2022
  • CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program

    April 7, 2022
  • CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors

    April 5, 2022
March
  • CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)

    March 17, 2022
  • CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook

    March 8, 2022
February
  • CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

    February 8, 2022
  • CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

    February 3, 2022
  • First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock

    February 1, 2022
January
  • New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents’ Antithrombotic Drug Removal Technology

    January 24, 2022
  • CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

    January 18, 2022
2021
December
  • CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

    December 21, 2021
  • CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

    December 20, 2021
Novemmber
  • CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference

    November 15, 2021
  • CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results

    November 4, 2021
October
  • CytoSorbents Comments on REMOVE Study Presentation

    October 20, 2021
  • First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

    October 14, 2021
  • CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

    October 12, 2021
  • CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

  • CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

    October 7, 2021
September
  • CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

    September 14, 2021
  • CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies

    September 13, 2021
  • CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

    September 10, 2021
  • CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

    September 8, 2021
  • Topline Results from CytoSorbents’ U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

    September 1, 2021
August
  • CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

    August 30, 2021
  • Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents’ DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

    August 12, 2021
  • CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

    August 3, 2021
July
  • CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE

    July 30, 2021
  • CytoSorbents to Report Second Quarter 2021 Operating and Financial Results

    July 19, 2021
  • CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery

    July 6, 2021
June
  • CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

    June 1, 2021
May
  • CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

    May 27, 2021
  • CytoSorb® Registered and Commercially Available in Singapore

    May 25, 2021
  • CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit

    May 19, 2021
  • CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

    May 11, 2021
  • CytoSorbents Reports First Quarter 2021 Financial and Operational Results

    May 4, 2021
April
  • CytoSorbents to Report Q1 2021 Operating and Financial Results

    April 27, 2021
  • U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

    April 19, 2021
March
  • CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

    March 29, 2021
  • CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery

    March 16, 2021
  • CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference

    March 12, 2021
  • CytoSorbents Announces 2020 Financial and Operational Results

    March 9, 2021
  • B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

    March 2, 2021
  • CytoSorbents to Report Fiscal 2020 Operating and Financial Results

    March 1, 2021
February
  • CytoSorbents to Present at the Cowen 41st Annual Health Care Conference

    February 24, 2021
  • CytoSorbents 2021: Leadership and Growth in the “New Normal”

    February 18, 2021
  • CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    February 16, 2021
  • National Institute for Health and Care Excellence (NICE) Issues Medtech Innovation Briefing on CytoSorb for Reducing Risk of Bleeding During Cardiac Surgery

    February 4, 2021
January
  • CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President – Global Regulatory Affairs

    January 21, 2021
  • CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care

    January 19, 2021
  • Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

    January 12, 2021
  • CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue

  • CytoSorbents Appoints James Komsa as Vice President – U.S. Sales and Marketing

    January 11, 2021
  • Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

    January 4, 2021
2020
December
  • CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and Marketing

    December 17, 2020
  • CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank

    December 10, 2020
  • Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study

    December 9, 2020
  • CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CARE

    December 2, 2020
November
  • CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients

    November 25, 2020
  • CytoSorbents to Present at the Piper Sandler 32nd Annual Healthcare Conference

    November 23, 2020
  • CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference

    November 12, 2020
  • CytoSorbents Reports Record Third Quarter 2020 Financial Results

    November 4, 2020
October
  • CytoSorbents to Report Q3 2020 Operating and Financial Results

    October 21, 2020
  • CytoSorbents and Aferetica Announce European Union Approval of the PerLife™ System and ECOS-300CY™ PerSorb™ Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant

    October 14, 2020
  • The U.S. Department of Defense Awards $1.1 Million to CytoSorbents to Optimize Development of HemoDefend-BGA™ for Life-saving Universal Plasma

    October 9, 2020
September
  • CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions

    September 21, 2020
  • CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020

    September 11, 2020
  • CytoSorbents Announces the “CytoSorb Therapy in COVID-19 ICU Patients” (CTC) Registry Is Actively Enrolling

    September 8, 2020
August
  • Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19

    August 24, 2020
  • CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19

    August 17, 2020
  • CytoSorbents Reports Record Second Quarter 2020 Financial Results

    August 4, 2020
  • CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date

    August 3, 2020
July
  • CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development

    July 31, 2020
  • CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data

    July 28, 2020
  • CytoSorbents to Report Q2 2020 Operating and Financial Results

  • CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock

    July 22, 2020
  • CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update

    July 20, 2020
  • CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock

  • C O R R E C T I O N — CytoSorbents Corporation

    July 8, 2020
June
  • CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding

    June 29, 2020
  • CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise

    June 24, 2020
  • CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials

    June 9, 2020
May
  • CytoSorbents Announces Virtual Annual Meeting

    May 27, 2020
  • CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery

    May 12, 2020
  • CytoSorbents Reports First Quarter 2020 Financial and Operational Results

    May 5, 2020
  • CytoSorbents Promotes Vincent J. Capponi to President

    May 4, 2020
April
  • CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program

    April 29, 2020
  • CytoSorbents to Report Q1 2020 Operating and Financial Results

    April 28, 2020
  • Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer

    April 27, 2020
  • Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery

    April 20, 2020
  • New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO

    April 15, 2020
  • U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection

    April 13, 2020
  • CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today

    April 3, 2020
March
  • CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care

    March 31, 2020
  • CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama

    March 25, 2020
  • CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities

    March 12, 2020
  • CytoSorbents Announces 2019 Financial and Operational Results

    March 5, 2020
  • CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits

    March 2, 2020
February
  • CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection

    February 19, 2020
  • CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report

    February 5, 2020
January
  • CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.

    January 29, 2020
  • CytoSorb, the Wuhan Coronavirus, and Cytokine Storm

    January 28, 2020
  • CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin

    January 22, 2020
  • CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter

    January 14, 2020
  • CytoSorbents to Present at Biotech Showcase™ 2020

    January 7, 2020
2019
December
  • CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference

    December 2, 2019
November
  • CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study

    November 25, 2019
  • CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference

    November 19, 2019
  • Dr. Eric Mortensen to Leave CytoSorbents At Year End

    November 6, 2019
  • CytoSorbents Reports Third Quarter 2019 Financial Results

    November 5, 2019
  • CytoSorbents Announces Additions to its International Clinical Team

    November 4, 2019
  • CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom

    November 1, 2019
October
  • CytoSorbents to Report Q3 2019 Operating and Financial Results

    October 30, 2019
  • CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia

    October 22, 2019
  • CytoSorbents to Present at The MicroCap Rodeo Investor Conference

    October 10, 2019
  • CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery

    October 4, 2019
  • CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

    October 2, 2019
September
  • CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock

    September 25, 2019
  • First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence

    September 16, 2019
  • World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis

    September 13, 2019
  • CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    September 9, 2019
August
  • CytoSorbents Highlights Recent Published Studies on CytoSorb

    August 28, 2019
  • CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022

    August 15, 2019
  • CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica

    August 13, 2019
  • CytoSorbents Reports Record Second Quarter 2019 Financial Results

    August 6, 2019
  • CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan

    August 5, 2019
July
  • CytoSorbents to Report Q2 2019 Operating and Financial Results

    July 30, 2019
June
  • CytoSorbents to Present at the Raymond James Life Sciences and MedTech Conference

    June 18, 2019
  • CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference

    June 11, 2019
  • CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference

    June 3, 2019
May
  • CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference

    May 20, 2019
  • CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance

    May 7, 2019
  • CytoSorbents to Report Q1 2019 Operating and Financial Results

    May 1, 2019
April
  • CytoSorbents Highlights the 6th International CytoSorb Users’ Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences

    April 24, 2019
  • CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London

    April 8, 2019
March
  • CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018

    March 7, 2019
  • CytoSorbents to Present at the Cowen 39th Annual Health Care Conference

    March 6, 2019
  • CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands

    March 5, 2019
February
  • CytoSorbents to Report Fiscal 2018 Operating and Financial Results

    February 28, 2019
  • CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference

    February 25, 2019
  • CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference

    February 5, 2019
  • CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial

    February 4, 2019
January
  • CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care

    January 22, 2019
  • CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results

    January 7, 2019
  • CytoSorbents To Highlight Progress at Biotech Showcase 2019

    January 4, 2019
2018
December
  • CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    December 21, 2018
November
  • CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference

    November 26, 2018
  • CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte’s 2018 Technology Fast 500™

    November 19, 2018
  • CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week

    November 12, 2018
  • CytoSorbents Reports Third Quarter 2018 Financial Results

    November 6, 2018
October
  • CytoSorbents to Report Q3 2018 Operating and Financial Results

    October 31, 2018
  • CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences

    October 18, 2018
  • CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference

    October 3, 2018
September
  • CytoSorb® Assigned Dedicated Procedure Code in Switzerland

    September 20, 2018
  • World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research

    September 13, 2018
  • CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA

    September 4, 2018
August
  • CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference

    August 28, 2018
  • CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter

    August 21, 2018
  • CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018

    August 2, 2018
July
  • CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide

    July 31, 2018
  • CytoSorbents to Report Q2 2018 Operating and Financial Results

    July 26, 2018
  • Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society

    July 9, 2018
June
  • CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes

    June 26, 2018
  • CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility

    June 12, 2018
  • CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference

    June 4, 2018
May
  • CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference

    May 21, 2018
  • CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use

    May 14, 2018
  • CytoSorbents Reports Strong First Quarter 2018 Financial Results

    May 8, 2018
  • CytoSorbents to Report Q1 2018 Operating and Financial Results

    May 2, 2018
April
  • CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery

    April 24, 2018
  • CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich

    April 9, 2018
  • CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank

    April 4, 2018
March
  • CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference

    March 28, 2018
  • CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference

    March 12, 2018
  • CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017

    March 8, 2018
  • CytoSorbents to Report Fiscal 2017 Operating and Financial Results

    March 1, 2018
February
  • CytoSorbents to Participate at the BTIG Healthcare Conference

    February 26, 2018
  • CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia

    February 15, 2018
  • CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference

    February 6, 2018
  • New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification

    February 1, 2018
January
  • CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter

    January 8, 2018
  • CytoSorbents To Provide Corporate Update at Biotech Showcase 2018

    January 3, 2018
2017
December
  • CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application

    December 21, 2017
  • CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    December 19, 2017
  • German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial

    December 11, 2017
November
  • CytoSorbents to Present at the LD Micro Main Event Investor Conference 2017

    November 29, 2017
  • CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017

    November 9, 2017
  • CytoSorbents Recognized on Deloitte’s 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America

  • CytoSorbents to Report Q3 2017 Operating and Financial Results

    November 2, 2017
  • CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia

    November 1, 2017
October
  • CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival

    October 19, 2017
  • CytoSorbents to Present at the 2017 BIO Investor Forum

    October 10, 2017
September
  • CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress

    September 26, 2017
  • Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®

    September 25, 2017
  • World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony

    September 14, 2017
  • Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation

    September 11, 2017
  • CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference

    September 6, 2017
  • CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium

    September 5, 2017
August
  • CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients

    August 14, 2017
  • CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017

    August 7, 2017
  • CytoSorbents to Report Q2 2017 Operating and Financial Results

    August 1, 2017
July
  • CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR

    July 17, 2017
  • CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma

    July 13, 2017
  • CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank

    July 5, 2017
June
  • CytoSorbents Announces Director and Management Open Market Stock Purchases

    June 15, 2017
  • CytoSorbents – A Leader in Blood Purification to Treat Deadly Inflammation – Teams with Investor Relations Firm LifeSci Advisors

    June 6, 2017
May
  • Dr. Eric R. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer

    May 30, 2017
  • CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference

    May 24, 2017
  • Aferetica and CytoSorbents Extend Exclusive “Life-saving” Partnership through 2021

    May 22, 2017
  • CytoSorbents Reports First Quarter 2017 Financial Results

    May 8, 2017
  • CytoSorbents Announces Positive REFRESH I Trial Results

    May 5, 2017
  • CytoSorbents to Report Q1 2017 Operating and Financial Results

    May 2, 2017
April
  • CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification

    April 24, 2017
  • CytoSorbents 2017 – Propelling the Company to the “Next Level”

    April 19, 2017
March
  • CytoSorbents Announces Pricing of Follow-On Offering

    March 31, 2017
  • CytoSorbents Announces Proposed Offering of Common Stock

    March 30, 2017
  • CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia

    March 28, 2017
  • CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference

    March 27, 2017
  • Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board

    March 22, 2017
  • CytoSorb® Treatment of HLH – The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy

    March 20, 2017
  • CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy’s Laboratories

    March 16, 2017
  • CytoSorbents Highlights Activities at the 22nd International Conference on Advances in Critical Care Nephrology

    March 7, 2017
  • CytoSorbents to Present at the Maxim Group – Haitong Securities Inaugural Healthcare Investor and Partnering Conference

    March 6, 2017
  • CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue

    March 3, 2017
  • CytoSorbents to Present at 37th Annual Cowen and Company Healthcare Conference

    March 2, 2017
February
  • CytoSorbents to Report Fiscal 2016 Operating and Financial Results

    February 24, 2017
  • CytoSorbents to Present at the 19th Annual BIO CEO & Investor Conference

    February 7, 2017
January
  • CytoSorbents Launches VetResQ™ for U.S. Veterinary Market

    January 20, 2017
  • CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results

    January 10, 2017
  • Fresenius Medical Care and CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb® Markets

    January 9, 2017
  • CytoSorbents To Provide Corporate Update at Biotech Showcase 2017

    January 3, 2017
2016
December
  • CytoSorbents Announces First Sales of New CytoSorb® CPB Procedure Pack for Cardiac Surgery

    December 20, 2016
  • CytoSorbents Receives $318,551 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    December 12, 2016
  • CytoSorb® Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany Expected to Catalyze Major Increases in Adoption and Sales of CytoSorb® in Germany

    December 7, 2016
  • CytoSorbents to Present at the LD Micro Main Event Investor Conference

    December 2, 2016
  • CytoSorb® Selected for NICE MedTech Innovation Briefing in the United Kingdom

    December 1, 2016
November
  • First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb®

    November 22, 2016
  • CytoSorbents Reports Highlights from the SepsEast 2016 Critical Care Congress

    November 17, 2016
  • Adrian Thomas Joins CytoSorbents to Drive Western European Sales

    November 15, 2016
  • CytoSorb® Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago

    November 7, 2016
  • CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg

    November 3, 2016
  • CytoSorbents to Report Q3 2016 Operating and Financial Results

    November 1, 2016
October
  • CytoSorbents Congratulates Kathleen Bloch as NJBIZ Public Company Chief Financial Officer of the Year

    October 17, 2016
  • CytoSorbents to Present at the 2016 BIO Investor Forum

    October 14, 2016
  • CytoSorbents and Foxx Medical Begin Saving Lives in Chile with CytoSorb®

    October 11, 2016
  • CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial

    October 5, 2016
  • International Marketing of CytoSorb® Commences at European Association for Cardio-Thoracic Surgery Conference

    October 3, 2016
September
  • New CytoSorbents Website Highlights Global Growth and Innovation

    September 29, 2016
  • CytoSorbents Expands CytoSorb® into Iran with Partner Arsak

    September 23, 2016
  • CytoSorbents Sponsors Sepsis Heroes Gala in Honor of World Sepsis Day

    September 15, 2016
  • Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership

    September 12, 2016
  • CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL

    September 8, 2016
  • CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment Conference

    September 7, 2016
August
  • CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb® Sales

    August 9, 2016
  • CytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers

    August 8, 2016
  • CytoSorbents to Report Q2 2016 Operating and Financial Results

    August 2, 2016
July
  • CytoSorbents Teams with Medial and Meditrade to Bring CytoSorb® to Hungary, Czech Republic, Slovakia, and Poland

    July 13, 2016
  • CytoSorbents to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

    July 6, 2016
  • CytoSorbents Closes $10 Million Debt Financing with Bridge Bank

    July 1, 2016
June
  • CytoSorbents Awarded $150,000 Phase I STTR Contract for Universal Plasma Development

    June 22, 2016
  • CytoSorbents and Palex Bring CytoSorb® to Spain and Portugal

    June 13, 2016
  • CytoSorbents Announces Fresenius Medical Care Initiates Sales of CytoSorb® in France, Poland and Scandinavia

    June 1, 2016
May
  • Independent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial

    May 27, 2016
  • CytoSorb® Achieves Final Product Registration in Russia

    May 18, 2016
  • CytoSorbents Continues Strong Growth in Q1 2016

    May 9, 2016
  • CytoSorbents Establishes Swiss Subsidiary

    May 6, 2016
  • CytoSorbents to Report Q1 2016 Operating and Financial Results

    May 2, 2016
April
  • CytoSorbents To Present At The 15th Annual Needham Healthcare Conference

    April 6, 2016
March
  • CytoSorbents Awarded $150,000 Phase I SBIR Contract for Fungal Mycotoxin Removal

    March 25, 2016
  • CytoSorbents Reports on Successful 3rd International CytoSorb® Users Meeting

    March 16, 2016
  • CytoSorbents to Host 3rd International CytoSorb® Users Meeting and ISICEM 2016 Symposium

    March 14, 2016
  • CytoSorbents Reports Record Quarterly and Full-Year 2015 Revenue

    March 9, 2016
  • CytoSorbents to Report Fiscal 2015 Operating and Financial Results

    March 2, 2016
February
  • Data Presented on First CytoSorb® Investigator-Initiated Septic Shock Study

    February 26, 2016
  • CytoSorbents to Exhibit at the 45th Society of Critical Care Medicine Congress

    February 18, 2016
  • CytoSorbents Announces 26th Symposium for Intensive Medicine and Intensive Care Agenda in Bremen, Germany

    February 16, 2016
  • CytoSorbents to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference

    February 4, 2016
  • CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    February 1, 2016
January
  • CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference

    January 28, 2016
  • CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs

    January 21, 2016
  • CytoSorbents 2016 – Driving Toward the Inflection Point

    January 11, 2016
  • CytoSorbents To Present at Biotech Showcase 2016

    January 4, 2016
2015
December
  • CytoSorbents Issues EAP Update

    December 21, 2015
  • CytoSorbents Expands Distribution of CytoSorb® to Vietnam

    December 15, 2015
  • CytoSorbents to Ring Opening Bell to Celebrate One Year NASDAQ Anniversary

    December 9, 2015
November
  • CytoSorbents Accelerates Growth in Q3 2015

    November 13, 2015
  • CytoSorbents To Meet With Investors at Brean Capital Life Sciences Summit and Stifel 2015 Healthcare Conference

    November 9, 2015
  • CytoSorbents to Report Q3 2015 Operating and Financial Results

    November 6, 2015
October
  • CytoSorbents To Advance HemoDefend™ Towards Commercialization with $1.5 Million Phase II SBIR Contract from NHLBI/NIH

    October 27, 2015
  • CytoSorbents Reports CytoSorb® Usage Grows to 8,000+ Human Treatments at Successful Second International Users Meeting

    October 5, 2015
September
  • CytoSorbents Ready for Second International CytoSorb® Users Meeting, ESICM and EACTS Conferences

    September 30, 2015
  • World Sepsis Day 2015: CytoSorbents Sponsors the SepsisUpdate 2015 Congress, Hugo Schottmuller Prize, and Sepsis Heroes Ceremony

    September 14, 2015
  • CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference

    September 2, 2015
August
  • CytoSorbents Reports Steady Growth in Q2 2015

    August 13, 2015
  • Saudi Food and Drug Authority Approves CytoSorb®

    August 10, 2015
  • CytoSorbents to Report Q2 2015 Operating and Financial Results

    August 6, 2015
July
  • CytoSorbents and TekMed Collaborate to Distribute CytoSorb® in Australia and New Zealand

    July 23, 2015
  • Veteran Healthcare Analyst Michael G. Bator Joins CytoSorbents Board of Directors

    July 15, 2015
June
  • CytoSorbents Corporation set to join Russell Microcap Index

    June 19, 2015
  • Privacy Information
  • Data protection
  • Disclaimer
  • contact
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.

CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world

X
U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection. Call 848-667-8990 to Order.